Login to Your Account


The delay in reporting data from the phase II trial by Ultragenyx Pharmaceutical Inc. with UX007 in glucose transporter type-1 deficiency syndrome patients with seizures may have tipped some investors that mixed results lay ahead with the compound.more »

Our Habitat for All Things Science
Specific lead identified in the fight against TB

Novel analogues of a class of antibacterial compounds isolated from soil bacteria could lead to the development of urgently needed new treatments for tuberculosis (TB), according to the findings of a study led by Australian researchers at the University of Sydney.

Worldwide, TB causes more deaths than any other infectious disease including HIV/AIDs. According to the WHO, there were an estimated 10.4 million new cases of TB and 1.8 million deaths in 2015, with 60 percent of all new cases occurring in Asia.



Partners in Focus